| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD276 |
| Uniprot No | Q5ZPR3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-245aa |
| 氨基酸序列 | LEVQVPEDPVVALVGTDATLCCSFSPEPGFSLAQLNLIWQLTDTKQLVHS FAEGQDQGSAYANRTALFPDLLAQGNASLRLQRVRVADEGSFTCFVSIRD FGSAAVSLQVAAPYSKPSMTLEPNKDLRPGDTVTITCSSYQGYPEAEVFW QDGQGVPLTGNVTTSQMANEQGLFDVHSILRVVLGANGTYSCLVRNPVLQ QDAHSSVTITPQRSPTG |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD275(B7-H3)重组蛋白的3篇代表性文献信息及摘要概括：
---
1. **文献名称**：*CD276/B7-H3 promotes the progression of malignant melanoma through regulating PDK1*
**作者**：Wang, Y., et al.
**摘要**：该研究通过重组CD276蛋白实验，揭示了其在黑色素瘤中通过激活PDK1/AKT信号通路促进肿瘤细胞增殖和转移的机制，提示其作为治疗靶点的潜力。
---
2. **文献名称**：*Structural basis of human B7-H3 isoforms in immune modulation and cancer progression*
**作者**：Zhang, G., et al.
**摘要**：利用重组CD276蛋白的晶体结构分析，阐明了不同剪接异构体的功能差异，发现某些异构体通过结合特定受体抑制T细胞活性，为开发靶向抗体药物提供结构依据。
---
3. **文献名称**：*Recombinant B7-H3 protein enhances tumor-associated macrophage immunosuppressive function in colorectal cancer*
**作者**：Chen, L., et al.
**摘要**：研究发现，重组CD276蛋白可通过激活STAT3通路增强肿瘤相关巨噬细胞的免疫抑制功能，促进结直肠癌的免疫逃逸，为联合靶向治疗提供新思路。
---
**注**：以上文献为虚拟示例，实际研究中建议通过PubMed或Web of Science检索关键词“CD276 recombinant protein”或“B7-H3 recombinant”获取真实文献。
CD276. also known as B7-H3. is a transmembrane protein belonging to the B7 family of immune checkpoint molecules. It plays a dual role in regulating immune responses, exhibiting both co-stimulatory and co-inhibitory effects depending on the cellular context. Structurally, CD276 contains immunoglobulin-like domains in its extracellular region, facilitating interactions with receptors on immune cells. Recombinant CD276 proteins are engineered versions of its extracellular domain, typically produced in mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications and functionality. These proteins often include tags (e.g., Fc or His tags) for purification and detection.
In cancer biology, CD276 has gained attention due to its overexpression in various malignancies, including carcinomas of the lung, breast, and prostate, where it correlates with poor prognosis. It suppresses T-cell activation and promotes tumor immune evasion by interacting with unknown receptors on immune cells. Recombinant CD276 proteins serve as critical tools for studying these mechanisms, enabling in vitro binding assays, antibody development, and structural studies. They are also used to generate antibodies for diagnostic applications and therapeutic targeting.
Therapeutic strategies leveraging CD276 include antibody-drug conjugates (e.g., Enoblituzumab), CAR-T cell therapies, and bispecific antibodies, many of which are in clinical trials. Notably, CD276’s restricted expression in normal tissues and high tumor specificity make it an attractive target for precision oncology. Beyond cancer, CD276 participates in autoimmune and inflammatory processes, though its roles remain less explored. Recent studies also suggest non-immunological functions in angiogenesis and tumor metastasis. Despite progress, challenges persist in fully elucidating its receptor interactions and signaling pathways. Recombinant CD276 proteins continue to accelerate translational research, bridging gaps between mechanistic studies and clinical applications in immunotherapy.
×
